Diabetes drug may offer symptom benefits in Parkinson’s trial
A four-week randomized trial in 12 people found symptom-score changes differed across two diabetes drugs and placebo, with more favorable trends for dapagliflozin.A four-week randomized trial in 12 people found symptom-score changes differed across two diabetes drugs and placebo, with more favorable trends for dapagliflozin.